Profile
Semaglutide
A long-acting version of the gut hormone GLP-1: how it works, what each product is approved for, and what the trials found
In this article
Key takeaways
Semaglutide is a long-acting version of the gut hormone GLP-1. Specific Novo Nordisk products are FDA-approved for type 2 diabetes, long-term weight reduction and cardiovascular risk reduction in defined groups, each use resting on large randomized trials.
- Evidence available
- Randomized trials in people
- Confidence
- High Several large double-blind, placebo-controlled trials with predefined outcomes report consistent results, and FDA approved the uses on that evidence.
- Main limitation
- The trials were funded by the manufacturer and followed people for about one to three and a half years, so effects over decades of use are not known.
At a glance
- Category
- Incretin Mimetics
- Mechanism
- GLP-1 receptor agonism with albumin-binding extension; enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic signaling
- Classification
- Modified GLP-1 analog (acylated peptide)
- Molecular weight
- 4,114 Da
- Half-life
- ~7 days (168 hours)
U.S. regulatory status
- Semaglutide injectionOzempic® (Novo Nordisk)
FDA-approved for this use
As an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes
Source 5, verified
- Semaglutide injectionOzempic® (Novo Nordisk)
FDA-approved for this use
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
Source 5, verified
- Semaglutide injectionOzempic® (Novo Nordisk)
FDA-approved for this use
To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Source 5, verified
- Semaglutide tabletsRybelsus® (Novo Nordisk)
FDA-approved for this use
As an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes
Source 7, verified
- Semaglutide tabletsRybelsus® (Novo Nordisk)
FDA-approved for this use
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events
Source 7, verified
- Semaglutide tabletsOzempic® tablets (Novo Nordisk)
FDA-approved for this use
As an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes
Source 7, verified
- Semaglutide tabletsOzempic® tablets (Novo Nordisk)
FDA-approved for this use
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events
Source 7, verified
- Semaglutide injectionWegovy® (Novo Nordisk)
FDA-approved for this use
With a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
Source 6, verified
- Semaglutide injectionWegovy® (Novo Nordisk)
FDA-approved for this use
With a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight and at least one weight-related comorbid condition
Source 6, verified
- Semaglutide injectionWegovy® (Novo Nordisk)
FDA-approved for this use
With a reduced-calorie diet and increased physical activity, for noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults; accelerated approval, continued approval may depend on a confirmatory trial
Source 6, verified
- Semaglutide tabletsWegovy® tablets (Novo Nordisk)
FDA-approved for this use
With a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
Source 6, verified
- Semaglutide tabletsWegovy® tablets (Novo Nordisk)
FDA-approved for this use
With a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight and at least one weight-related comorbid condition
Source 6, verified
Semaglutide is a modified, long-lasting version of GLP-1, a hormone the gut releases after eating. Specific products made by Novo Nordisk are FDA-approved for type 2 diabetes, for long-term weight reduction in adults with obesity or with overweight and a weight-related condition, and for several heart, kidney and liver uses that differ from product to product 5,6,7. The evidence for these uses comes from large randomized trials, all funded by Novo Nordisk, that followed people for between about one and three and a half years 1,2,4.
Which semaglutide products are approved, and for what
FDA approves a product for a use, not a molecule in general. These are the approved uses in each product’s label, checked on October 18, 2026:
- Ozempic® injection (Novo Nordisk). As an adjunct to diet and exercise, to improve blood sugar control in adults with type 2 diabetes; to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained decline in kidney function, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease 5.
- Rybelsus® and Ozempic® tablets (Novo Nordisk). As an adjunct to diet and exercise, to improve blood sugar control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them 7.
- Wegovy® injection (Novo Nordisk). With a reduced-calorie diet and more physical activity: to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce excess body weight and keep it off long term in adults and children aged 12 and older with obesity, and in adults with overweight and at least one weight-related condition; and, under accelerated approval, for noncirrhotic MASH (formerly called NASH) with moderate to advanced liver fibrosis in adults 6.
- Wegovy® tablets (Novo Nordisk). Approved by FDA on December 22, 2025 8. With a reduced-calorie diet and more physical activity: to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition 6. The tablets’ label does not include children or MASH 6.
The MASH approval is an accelerated approval based on improvement in liver tissue, and keeping it may depend on a confirmatory trial showing clinical benefit 6. A use that is not on a product’s label is not an approved use of that product.
How semaglutide differs from natural GLP-1
Natural GLP-1 is a 30-amino-acid hormone that lasts only about 1.5 minutes in the blood after intravenous administration 9. Semaglutide keeps 94 percent of its sequence 5 and changes it at three positions, 8, 26 and 34 3. The change at position 8, to an amino acid called Aib, protects the molecule from the enzyme DPP-4. At position 26 a fatty-acid chain is attached, which makes semaglutide bind to albumin, one of the most abundant proteins in blood 9.
Albumin binding slows the molecule’s clearance by the kidneys and protects it from breakdown. The result is an elimination half-life of about one week, compared with minutes for the natural hormone 5.
What semaglutide does in the body
According to the labels, semaglutide increases insulin release and lowers glucagon release, both in a glucose-dependent way: the effect is strongest when blood sugar is high 5. It also causes a minor delay in stomach emptying in the period right after a meal 5. GLP-1 receptors are present in brain areas involved in appetite, and in animal studies semaglutide reached and activated neurons in regions that regulate food intake 6.
Some of what semaglutide does is still unexplained. The labels state that the mechanism behind its cardiovascular risk reduction has not been established 6, and the same is true for the kidney outcomes 5.
What the major trials found
SUSTAIN-6 enrolled 3,297 adults with type 2 diabetes, 83 percent of whom already had cardiovascular disease, chronic kidney disease or both 1. Over 104 weeks, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.6 percent of the semaglutide group and 8.9 percent of the placebo group (hazard ratio 0.74; 95% CI 0.58 to 0.95) 1. The trial was designed to rule out extra cardiovascular risk, not to prove a benefit. It also found more retinopathy complications in the eye with semaglutide (hazard ratio 1.76; 95% CI 1.11 to 2.78) 1.
SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or more, and no diabetes 2. Over a mean follow-up of 39.8 months, the same combined outcome occurred in 6.5 percent of the semaglutide group and 8.0 percent of the placebo group (hazard ratio 0.80; 95% CI 0.72 to 0.90) 2. Side effects led 16.6 percent of people on semaglutide to stop it for good, against 8.2 percent on placebo 2.
STEP 1 enrolled 1,961 adults with obesity, or with overweight and at least one weight-related condition, and no diabetes 4. Everyone also received a lifestyle intervention. After 68 weeks, average body weight had changed by −14.9 percent with semaglutide and −2.4 percent with placebo 4. Half of the semaglutide group (50.5 percent) lost at least 15 percent of their body weight, compared with 4.9 percent on placebo 4.
All three trials were funded by Novo Nordisk 1,2,4, and SELECT and STEP 1 tested the injection 2,4. Their results describe the people they enrolled; they do not show what happens over decades of use.
Side effects and warnings
Stomach and gut effects are the most common. In the Wegovy® injection weight-reduction trials, nausea was reported by 44 percent of people on Wegovy® and 16 percent on placebo, diarrhea by 30 and 16 percent, vomiting by 24 and 6 percent, and constipation by 24 and 11 percent 6. In STEP 1 these effects were usually mild to moderate and faded with time, but 4.5 percent of the semaglutide group stopped treatment because of them, compared with 0.8 percent on placebo 4.
Every semaglutide label carries a boxed warning: in rodents, semaglutide causes thyroid C-cell tumors, and it is not known whether it causes these tumors, including medullary thyroid carcinoma, in humans 5,6,7. Semaglutide is not to be used by people with a personal or family history of medullary thyroid carcinoma, people with multiple endocrine neoplasia syndrome type 2, or people who have had a serious allergic reaction to semaglutide or the product’s ingredients 5,6,7.
The Wegovy® label lists further warnings, including acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and inhaling stomach contents during general anesthesia or deep sedation 6. The prescribing information is the complete list.
Sources
9 sources. Numbers in the text link to the entry they cite.
- 1.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016.
Randomized controlled trial PMID 27633186 DOI 10.1056/NEJMoa1607141Checked October 18, 2026
Cited for: SUSTAIN-6: 3,297 adults with type 2 diabetes, 83.0% with CVD, CKD or both; 104 weeks; primary outcome 6.6% vs 8.9% (HR 0.74; 95% CI 0.58-0.95; noninferiority); retinopathy complications HR 1.76 (1.11-2.78); funded by Novo Nordisk
Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)
- 2.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023.
Randomized controlled trial PMID 37952131 DOI 10.1056/NEJMoa2307563Checked October 18, 2026
Cited for: SELECT: 17,604 adults aged 45 or older with CVD and BMI 27 or more, no diabetes; subcutaneous semaglutide; mean follow-up 39.8 months; primary outcome 6.5% vs 8.0% (HR 0.80; 95% CI 0.72-0.90); permanent discontinuation for adverse events 16.6% vs 8.2%; funded by Novo Nordisk
Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)
- 3.
Clinical Pharmacokinetics of Semaglutide: A Systematic Review
Yang XD, Yang YY. Drug Des Devel Ther. 2024.
Systematic review PMID 38952487 DOI 10.2147/DDDT.S470826Checked October 18, 2026
Cited for: Semaglutide is 94% homologous to human GLP-1, with modifications at positions 8, 26 and 34 that prolong its half-life
- 4.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021.
Randomized controlled trial PMID 33567185 DOI 10.1056/NEJMoa2032183Checked October 18, 2026
Cited for: STEP 1: 1,961 adults without diabetes, BMI 30 or more (27 or more with a weight-related condition); subcutaneous semaglutide plus lifestyle intervention; 68 weeks; weight change -14.9% vs -2.4%; 15% or more loss in 50.5% vs 4.9%; GI effects mostly mild to moderate and transient; GI discontinuation 4.5% vs 0.8%; funded by Novo Nordisk
Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)
- 5.
OZEMPIC (semaglutide) injection, for subcutaneous use: prescribing information (effective 2026-06-01)
Novo Nordisk. DailyMed. 2026.
Product labeldailymed.nlm.nih.govChecked October 18, 2026
Cited for: Ozempic® indications (section 1); 94% sequence homology to GLP-1; albumin binding, DPP-4 stability; glucose-dependent insulin and glucagon effects; minor delay in early postprandial gastric emptying; kidney mechanism not established; elimination half-life about 1 week; boxed warning; contraindications
Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)Back to text (h)Back to text (i)
- 6.
WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use: prescribing information (effective 2026-06-18)
Novo Nordisk. DailyMed. 2026.
Product labeldailymed.nlm.nih.govChecked October 18, 2026
Cited for: Wegovy® injection and tablet indications, including accelerated approval for MASH (section 1); brain GLP-1 receptors and animal neuron activation; CV mechanism not established (12.1); adverse reaction rates (Table 3); boxed warning; contraindications; warnings 5.2-5.10
Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)Back to text (h)Back to text (i)Back to text (j)Back to text (k)
- 7.
RYBELSUS (semaglutide) tablets, for oral use; OZEMPIC (semaglutide) tablets, for oral use: prescribing information (effective 2026-01-30)
Novo Nordisk. DailyMed. 2026.
Product labeldailymed.nlm.nih.govChecked October 18, 2026
Cited for: Rybelsus® and Ozempic® tablet indications (section 1); boxed warning; contraindications
Back to text (a)Back to text (b)Back to text (c)Back to text (d)
- 8.
Drugs@FDA: NDA 218316, WEGOVY (semaglutide) tablets, Novo Nordisk
U.S. Food and Drug Administration. Drugs@FDA. 2025.
Regulatory documentaccessdata.fda.govChecked October 18, 2026
Cited for: Original approval of Wegovy® tablets (NDA 218316, new dosage form) on 2025-12-22
- 9.
The Discovery and Development of Liraglutide and Semaglutide
Knudsen LB, Lau J. Front Endocrinol (Lausanne). 2019.
Review PMID 31031702 DOI 10.3389/fendo.2019.00155Checked October 18, 2026
Cited for: GLP-1 is a 30-amino-acid hormone, half-life 1.5 minutes after intravenous dosing; Aib at position 8 gives DPP-IV stability; fatty acid attached at lysine 26 for albumin binding; albumin among the most abundant plasma proteins
